Usually biotech stock uses a lot of money upfront on R&D to get their product to a commercialisation stage, then revenue starts coming in and staff cost usually decrease, unless they are working on other development. Given AHZ's revenue is already pass $20M, they won't be privily to substantial R&D tax refund anymore, so are they planning to sell their Infusion part of the company (which is on track to bring in $20M out of the $30M in revenue this year) so they can take advantage of this R&D tax refund again, hence R&D has started to increase again.........along with staff cost????
Interesting strategy.......
AHZ Technical Analysis, page-109
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |